Industry Trend Analysis - Growing Antibiotic Resistance Creates Larger Market For Baxdela - AUG 2017


BMI View : The FDA approval of Melinta Therapeutics ' Baxdela will see the company generate it s first revenues, which makes it a more attractive target. Increasing antibiotic resistance to first- generation antibiotics will drive Baxdela ' s growth, but it could face resistant bacteria species if overused and given to misdiagnosed patients .

Melinta Therapeutics is targeting a growing market with its US approval of its second-generation antibiotic. Antibiotic resistance has seen increased publicity and funding, which is driving growth in this area.

The FDA has approved Melinta's Baxdela (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Baxdela is a fluoroquinolone that exhibits activity against both gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and is available in both intravenous (IV) and oral formulations. It offers a new option for treatment of adult patients with ABSSSI including hospital-treated skin infections in oral and IV formulations as monotherapy.

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial